Healthcare shares were generally flat in pre-market trade on Monday.
In healthcare stocks news, ImmunoCellular Therapeutics ( IMUC ) shares were up 12% after it posted positive data on a study on a dendritic cell-based immunotherapeutic vaccine.
And, Cytokinetics ( CYTK ) shares fell 15% in Monday's pre-market session, after the biopharmaceutical company released data showing in a Phase IIb trial of Tirasemtiv in patients with amyotrophic lateral sclerosis, the drug--which is the lead candidate from its skeletal-muscle-contractility program--failed to meet the primary efficacy endpoint.
CYTK was, nearing the low end of its 52-week range of $3.96 to $14.28.
Finally, Puma Biotechnology ( PBYI ) has announced the presentation of positive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2 positive metastatic breast cancer that has metastasized to the brain. The data was presented in a poster at the American Society of Clinical Oncology 2014 Annual Meeting in Chicago, Illinois.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
